

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 22578-0005US1	Application No. 10/535,345
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Semple, et al.	
		Filing Date February 15, 2006	Group Art Unit 1626

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	1	WO 2006114581	11-02-2006	PCT				
	2	WO 2006052569	05-18-2006	PCT				
	3	WO 2006026273	03-09-2006	PCT				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	4	Wilson, Robert D., et al., "Development of a Scaleable Synthesis of a Partial Nicotinic Acid Receptor Agonist", Organic Process Research & Development, Article APAP, DOI: 10.1021/op800290t (March 16, 2009)
	5	Semple, Graeme, et al., "3-(1H-Tetrazol-5-yl)-1,4,5,6-tetrahydro- cyclopentapyrazole (MK-0354): A Partial Agonist of the Nicotinic Acid Receptor, G-Protein Coupled Receptor 109a, with Antilipolytic but No Vasodilatory Activity in Mice", Journal of Medicinal Chemistry (2008), 51(16), 5101-5108
	6	Press Release, Arena Pharmaceuticals, Arena Pharmaceuticals Announces Update on Partnership With Merck in Development of Niacin Receptor Agonists, San Diego, CA (September 25, 2006)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	